TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
CEO: James A. Bianco. Company website
TuHURA Biosciences, Inc. (HURA) trades at $2.10, up 0.48% on the day, as of Sep 20, 2026 14:59 UTC.
TuHURA Biosciences, Inc. has a market capitalisation of $133.73M, calculated from the live HURA share price and shares outstanding.
HURA has no meaningful price-to-earnings ratio: TuHURA Biosciences, Inc. lost $0.54 per share over the last twelve months, and a P/E is only defined on positive earnings.
TuHURA Biosciences, Inc. generated revenue of $0.00 over the trailing twelve months.
HURA has traded between $0.41 and $3.43 over the past 52 weeks, and the last price is 38.8% below that high.
Yes. TuHURA Biosciences, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
Wall Street analysts rate HURA Buy.
TuHURA Biosciences, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
James A. Bianco is the chief executive of TuHURA Biosciences, Inc., which employs 22 people.
QFI Terminal shows HURA with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open HURA in Terminal See plans